^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/10/2023
Excerpt:
Biliary Tract Cancer….Primary Treatment for Unresectable and Metastatic Disease….Nivolumab + ipilimumab was added as a category 2B recommendation for TMB-H tumors
